chronic heart failure with reduced ejection fraction (NYHA Class III)

DBCOND0025715Cardiovascular Diseases

chronic heart failure with reduced ejection fraction (NYHA Class III) is the indication for 8 drugs in DrugBank. It is covered by 8 curated, structured indications.

Also known as: moderate Heart failure · NYHA Class III Congestive Heart Failure · NYHA Class III Heart Failure · Heart Failure NYHA Class III · Heart failure, moderate
Classified under: Cardiovascular Diseases
Indicated drugs: Candesartan cilexetil
Carvedilol
Furosemide
Iobenguane sulfate I-123
Metoprolol
Perindopril
Spironolactone
Valsartan

Resolves to

Vocabularies

SNOMED CT48447003MedDRA10007558UMLSC0264716

What you can answer from here — as of October 22, 2026

8Indicated drugsWith each drug's targets and mechanism

Listed above

8Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

13Clinical trialsPhase, status and sponsor resolved per trial

3Contraindicated drugsDrugs whose labels contraindicate them in this condition

Which approved drugs for chronic heart failure with reduced ejection fraction (NYHA Class III) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account